Guardion Health Sciences, Inc. (NASDAQ: GHSI) shares rose 26.25% to $0.4689 in the post-market hours Wednesday. There’s no news specific to stock, so investors might want to take this as a bullish sign. , The only information that might have influenced this rise was on December 16, 2020, when the company revealed that it had made progress in developing a new vision support/energy drink, Epiq-V, which has been under development for the United States and international markets.
Lumega-Z is marketed mainly to the children market as an eye health and support product. At the same time, Epiq-V is being developed for an adult market as a visual attention and energy drink that helps support video gaming and other close-up device-viewing demands of the teens market. The initial round of testing has been completed, and the final round is currently underway and is expected to be completed by the end of the first quarter of 2021. For the Asian market, specifically China, Epiq-V has already secured trademark protection (using Chinese characters) for its brand name. A trademark application has been submitted for approval in the United States.
The company’s interim President and Chief Executive Officer, David Evans, Ph.D., said, “We have long emphasized the importance of accessing new markets with our unique formulation capabilities, and we built up our Asia presence during 2020.” With the development and eventual distribution of Epiq-V, we hope to expand our presence in Asia by providing a product line that is designed to support overall ocular health and attention.”